ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

bimagrumab

Also written as “Bimagrumab”, “BYM338” and “LY3985863”.

Its studies are mostly in Myositis, Inclusion Body · Obesity · Sarcopenia · Cachexia · Heart Failure, Diastolic, led by 2 companies.

Drug pageBimagrumab: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 15, 201318 company-led studies, 1 open or runningAcquisition: Lilly acquired Versanis Bio, Aug 2023Next primary completion: Jul 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only120 open or runningphase 3since Aug 15, 2013Aug 12, 2011none ahead
Eli Lilly61 open or runningphase 2since Oct 16, 2022Oct 16, 2022Jul 2029phase 2 · NCT07920887
  • Named in Eli Lilly’s own pipeline as Bimagrumab, phase 2, as of Oct 29, 2026 (source).

Also a collaborator on its studies: Versanis Bio.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

How Novartis relates to it is not in the registry or these sources.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. Dates ahead are the sponsors’ estimates.

  1. Oct 16, 2022First study: phase 2 study in ObesityFirst studyNCT05616013 · 507 enrolled · United States, Australia, New Zealand
  2. Aug 14, 2023Lilly acquired Versanis BioAcquisitionWith it bimagrumab, its lead asset · completed · Lilly (release)
  3. Oct 14, 2024Phase 2 study in ObesityNCT06643728 · 252 enrolled · United States
  4. Mar 18, 2025Phase 1 study in HealthyNCT06890611 · 125 enrolled · United States
  5. Mar 24, 2025Phase 2 study in ObesityNCT06901349 · United States, Argentina, Canada and more
  6. Jun 12, 2025Phase 1 study in HealthyNCT07030127 · 24 enrolled · China
  7. Oct 29, 2026Phase 2 study in Heart Failure, DiastolicNCT07920887 · 540 planned · United States, Hungary, Italy and more

Ahead

  1. Jul 2029Primary completion: phase 2 study in Heart Failure, DiastolicNCT07920887

TargetBeta

“A human monoclonal antibody directed against type II activin receptors (ActRII; ActR2), with potential muscle-sparing and anti-cachectic activities. Upon administration, bimagrumab binds to ActRII, which prevents the binding of the natural ligands, myostatin and activin, to activin receptors and …”NCIt, read by Claude
“Activin receptor type-2B antagonist”ChEMBL 37, by rule

Studies

All 6 Eli Lilly leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07920887Heart Failure, Diastolic · United States, Hungary, Italy and more2Not yet recruitingJul 2029540
NCT07030127Healthy · China1CompletedFeb 24, 202624
NCT06901349Obesity · United States, Argentina, Canada and more2WithdrawnJun 10, 20250
NCT06890611Healthy · United States1CompletedSep 26, 2025125
NCT06643728Obesity · United States2CompletedJan 16, 2026252
NCT05616013Obesity · United States, Australia, New Zealand2CompletedMay 16, 2024507

How it is read

Names in the registry

  • “Bimagrumab”, 6 entries
  • “BYM338”, 4 entries
  • “bimagrumab”, 3 entries
  • “LY3985863”, 1 entry
  • “BYM338 10 mg/kg”, 1 entry

Codes read as this program: LY3985863.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.